Table 4.
Clinicopathological features | n | β-catenin | TCF-4 | Survivin | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
− | + | Positive rate | P | − | + | Positive rate | P | − | + | Positive rate | P | ||
Age | |||||||||||||
≤ 45 | 86 | 27 | 59 | 0.69 | 0.166 | 26 | 60 | 0.7 | 0.64 | 29 | 57 | 0.66 | 0.345 |
> 45 | 78 | 17 | 61 | 0.78 | 21 | 57 | 0.73 | 21 | 57 | 0.73 | |||
Gender | |||||||||||||
Male | 117 | 28 | 89 | 0.76 | 0.186 | 32 | 85 | 0.73 | 0.559 | 32 | 85 | 0.73 | 0.169 |
Female | 47 | 16 | 31 | 0.66 | 15 | 32 | 0.68 | 18 | 29 | 0.62 | |||
Smoking history | |||||||||||||
Yes | 107 | 24 | 83 | 0.78 | 0.082 | 32 | 75 | 0.7 | 0.628 | 32 | 75 | 0.7 | 0.825 |
No | 57 | 20 | 37 | 0.65 | 15 | 42 | 0.74 | 18 | 39 | 0.68 | |||
Family history | |||||||||||||
Yes | 95 | 23 | 83 | 0.87 | 0.193 | 27 | 68 | 0.72 | 0.937 | 26 | 69 | 0.73 | 0.309 |
No | 69 | 21 | 48 | 0.7 | 20 | 49 | 0.71 | 24 | 45 | 0.65 | |||
EBV DNA | |||||||||||||
Positive | 116 | 15 | 101 | 0.87 | <0.001 | 24 | 92 | 0.79 | 0.001 | 27 | 89 | 0.77 | 0.002 |
Negative | 48 | 29 | 19 | 0.40 | 23 | 25 | 0.52 | 23 | 25 | 0.52 | |||
EBV-VCA-IgA | |||||||||||||
Positive | 111 | 21 | 90 | 0.81 | 0.001 | 22 | 89 | 0.80 | <0.001 | 28 | 83 | 0.75 | 0.034 |
Negative | 53 | 23 | 30 | 0.57 | 25 | 28 | 0.53 | 22 | 31 | 0.58 | |||
EBV-EA-IgA | |||||||||||||
Positive | 64 | 4 | 60 | 0.94 | <0.001 | 5 | 59 | 0.92 | <0.001 | 7 | 57 | 0.89 | <0.001 |
Negative | 100 | 40 | 60 | 0.60 | 42 | 58 | 0.58 | 43 | 57 | 0.57 | |||
T stage | |||||||||||||
T1 | 28 | 4 | 0.14 | <0.001 | 18 | 10 | 0.36 | <0.001 | 16 | 12 | 0.43 | 0.004 | |
T2 | 52 | 16 | 36 | 0.69 | 12 | 40 | 0.77 | 19 | 33 | 0.63 | |||
T3 | 48 | 2 | 46 | 0.96 | 15 | 33 | 0.69 | 13 | 35 | 0.73 | |||
T4 | 36 | 2 | 34 | 0.94 | 2 | 34 | 0.94 | 2 | 34 | 0.94 | |||
N stage | |||||||||||||
N0 | 27 | 25 | 2 | 0.07 | <0.001 | 20 | 7 | 0.26 | <0.001 | 16 | 11 | 0.41 | 0.006 |
N1 | 41 | 17 | 24 | 0.59 | 11 | 30 | 0.73 | 18 | 23 | 0.56 | |||
N2 | 47 | 1 | 46 | 0.98 | 9 | 38 | 0.81 | 8 | 39 | 0.83 | |||
N3 | 49 | 24 | 48 | 0.98 | 7 | 42 | 0.86 | 8 | 41 | 0.84 | |||
Clinicopathological stages | |||||||||||||
I | 19 | 16 | 3 | 0.16 | <0.001 | 13 | 6 | 0.32 | 0.002 | 12 | 7 | 0.37 | 0.021 |
II | 22 | 10 | 12 | 0.55 | 13 | 9 | 0.41 | 11 | 11 | 0.5 | |||
III | 35 | 10 | 25 | 0.71 | 8 | 27 | 0.77 | 10 | 25 | 0.71 | |||
IVa | 49 | 6 | 43 | 0.88 | 8 | 41 | 0.84 | 12 | 37 | 0.76 | |||
IVb | 39 | 2 | 37 | 0.95 | 5 | 34 | 0.87 | 5 | 34 | 0.87 | |||
Histological classification | |||||||||||||
Differentiated non-keratinized | 113 | 27 | 86 | 0.76 | 0.207 | 31 | 82 | 0.73 | 0.606 | 32 | 81 | 0.72 | 0.370 |
Undifferentiated non-keratinized | 51 | 17 | 34 | 0.67 | 16 | 35 | 0.69 | 18 | 33 | 0.65 |
The standard of family history of nasopharyngeal carcinoma was at least two or more NPC patients in the two generation, and is the first-degree relatives. The standard of smoking history was to smoke one cigarette every day for 6 months or more
TCF-4 T-cell factor-4, NPC nasopharyngeal carcinoma, T tumor, N node, + positive expression, − negative expression